Genentech’s Innovative ADC Kadcyla Approved for Early-Stage Breast Cancer, Validating a Novel Clinical Development Paradigm

On the 4th, Genentech announced that the United StatesFDAApproval of the expanded indication for its antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine) as adjuvant therapy for patients with HER2-positive early-stage breast cancer who have residual invasive disease after neoadjuvant therapy.Breast Cancerpatients. The approval of this therapy not only provides a new treatment option for patients with early-stage breast cancer, but also validates the conduct of studies targeting patients with early-stage high-risk breast cancerClinical Trialnew model.

Breast cancer is one of the most common cancers among women worldwide. According to statistics from the American Cancer Society, there were approximately 271,000 new cases of breast cancer in the United States in 2019, and 42,000 patients died from the disease. Among the various subtypes of breast cancer, approximately 15%–20% are HER2-positive. In these patients, cancer cells express the HER2 protein on their surface.

For these patients, HER2-targeted therapies are expected to deliver favorable treatment outcomes. Kadcyla is one such therapy. As an antibody-drug conjugate (ADC), it comprises trastuzumab, the primary active ingredient in Herceptin, which targets HER2, linked to the chemotherapy agent DM1. Designed to bind to HER2-expressing cancer cells, this drug aims to destroy them. Currently, Kadcyla is the only ADC approved in the United States for the treatment of both early-stage and metastatic HER2-positive breast cancer.

In a phase 3 trial named KATHERINEClinical TrialIn the study, the efficacy of Kadcyla was validated. Specifically, compared with patients receiving Herceptin, those treated with Kadcyla exhibited a significant 50% reduction in the risk of breast cancer recurrence or all-cause mortality (HR=0.50, 95% CI: 0.39–0.64, p<0.0001). At the 3-year mark, 88.3% of patients receiving Kadcyla remained free from breast cancer recurrence, compared to 77.0% in the control group.

It is worth mentioning that, in order to accelerate the drug development and review process, the clinical trial design and review process of this drug utilizedFDAMultiple acceleration channels provided. InClinical TrialsIn the design, researchers utilized the surrogate endpoint of pathological complete response (pCR), introduced by the FDA, as the criterion to screen patients with early-stage breast cancer who had received neoadjuvant therapy. According toFDAGuidelines: pCR is defined as the absence of residual invasive (and in situ) disease in the resected breast and sampled regional lymph nodes following completion of neoadjuvant therapy.Tumor. In the KATHERINE clinical trial, only patients who did not achieve pCR after neoadjuvant therapy were included in the next stepClinical Trials, receiving adjuvant therapy with Kadcyla or Herceptin.

This for high-risk early-stage breast cancer patientsClinical TrialThis design not only enables earlier completion of patient enrollment but may also help generate trial results sooner. Director of the Office of Hematology and Oncology Products, U.S. FDA,FDACenter for Drug Evaluation and Research Hematology andTumorRichard Pazdur, M.D., Acting Director of the Office of Hematology and Oncology Products, commented in The New England Journal of Medicine, elucidating thisClinical TrialsThe Advantages of the Design in Accelerating the Development of New Drugs for Breast Cancer and Benefiting High-Risk Early-Stage Patients.

The approval pathway for this drug isFDAReal-timeTumorThe Real-Time Oncology Review (RTOR) and the Assessment Aid pilot program facilitated the approval of this therapy just 12 weeks after submission. This marks the first drug approved for Genentech under the RTOR pilot program. In its press release, Genentech stated that the pilot program is exploring a more efficient review process to ensure that safe and effective therapies reach patients as early as possible.

With the approval of this drug, patients with early-stage breast cancer are expected to gain new treatment options, offering them the best hope for a cure. “This approval is significant for the treatment of HER2-positive early-stage breast cancer. By working with U.S.FDA“Through close collaboration and participation in the RTOR pilot program, we have made Kadcyla available to patients with residual disease after neoadjuvant therapy in a timeframe far shorter than anticipated,” said Dr. Sandra Horning, Chief Medical Officer and Head of Global Product Development at Genentech. “With every small step we take to reduce the risk of disease recurrence, we move closer to our goal of ensuring that every patient with early-stage breast cancer has the greatest possible chance of cure!”

We look forward to this drug bringing better prognoses for patients with early-stage breast cancer! We also hope to help this drug gain approval.Clinical TrialsThis enables innovations from the review process to be adopted by more drug developers, accelerating the availability of other new medicines to patients.BioValleyBioon.com）